Overview

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Trial to evaluate efficacy of dual blockade with two anti-HER2 agents with or without chemotherapy backbone within the ADAPT trial.
Phase:
Phase 2
Details
Lead Sponsor:
West German Study Group
Collaborator:
Roche Pharma AG
Treatments:
Paclitaxel
Pertuzumab
Taxane
Trastuzumab